Ascendiant Capital Markets Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $65.00

Plus Therapeutics (NASDAQ:PSTV) had its price objective reduced by analysts at Ascendiant Capital Markets from $475.00 to $65.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

PSTV has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $25.00 target price (down from $50.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Thursday, January 22nd. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. Lake Street Capital began coverage on Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $50.00 target price for the company. Finally, Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Plus Therapeutics presently has an average rating of “Hold” and a consensus target price of $58.00.

Plus Therapeutics Stock Up 8.6%

Shares of PSTV stock opened at $3.17 on Thursday. The business has a 50-day moving average price of $6.23 and a two-hundred day moving average price of $11.20. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $30.50. The firm has a market cap of $21.75 million, a P/E ratio of -0.10 and a beta of 1.03.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Thursday, March 12th. The company reported $6.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $6.28. The firm had revenue of $1.37 million for the quarter, compared to the consensus estimate of $1.23 million. As a group, research analysts expect that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PSTV. Jane Street Group LLC bought a new position in Plus Therapeutics during the 2nd quarter valued at approximately $41,000. Susquehanna International Group LLP bought a new position in Plus Therapeutics during the 3rd quarter valued at approximately $46,000. Scientech Research LLC bought a new position in Plus Therapeutics during the 3rd quarter valued at approximately $100,000. XTX Topco Ltd bought a new position in Plus Therapeutics during the 4th quarter valued at approximately $127,000. Finally, State Street Corp raised its position in Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the last quarter. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.